{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:30Z","timestamp":1786998390227,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100028726","name":"Oklahoma Restaurant Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xphs.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:55:49Z","timestamp":1718200549000},"page":"2837-2842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Robust Chromatographic Method for Drug Release profiling of liposomal doxorubicin HCl"],"prefix":"10.1016","volume":"113","author":[{"given":"Isabelle I.","family":"Niyonshuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savithra","family":"Jayaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-6690","authenticated-orcid":false,"given":"Thilak","family":"Mudalige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xphs.2024.06.005_bib0001","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.xphs.2024.06.005_bib0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"issue":"13","key":"10.1016\/j.xphs.2024.06.005_bib0003","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2024.06.005_bib0004","doi-asserted-by":"crossref","first-page":"e00387","DOI":"10.7554\/eLife.00387","article-title":"How does doxorubicin work?","volume":"1","author":"Patel","year":"2012","journal-title":"Elife"},{"issue":"11","key":"10.1016\/j.xphs.2024.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.bbabio.2007.08.006","article-title":"Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart","volume":"1767","author":"Tokarska-Schlattner","year":"2007","journal-title":"Biochim Biophys Acta"},{"issue":"25","key":"10.1016\/j.xphs.2024.06.005_bib0006","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the Good, the Bad and the Ugly Effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2024.06.005_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2017","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0005-2736(98)00175-8","article-title":"Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient","volume":"1415","author":"Li","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.xphs.2024.06.005_bib0010","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3109\/03639045.2014.954582","article-title":"Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions","volume":"41","author":"Shibata","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.06.005_bib0011","first-page":"229","article-title":"Pegylated liposomal doxorubicin in ovarian cancer","volume":"1","author":"Andrew E Green","year":"2006","journal-title":"Intl J Nanomed"},{"issue":"18","key":"10.1016\/j.xphs.2024.06.005_bib0012","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.xphs.2024.06.005_bib0013","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1570-0232(02)00395-1","article-title":"Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography","volume":"779","author":"Chin","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"10.1016\/j.xphs.2024.06.005_bib0014","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2024.06.005_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10611869609015970","article-title":"Liposomal doxorubicin","volume":"4","author":"Tardi","year":"1996","journal-title":"J Drug Target"},{"key":"10.1016\/j.xphs.2024.06.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118906","article-title":"Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS)","volume":"574","author":"Ansar","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.06.005_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2020.115991","article-title":"A review on various analytical methods for determination of anthracyclines and their metabolites as anti\u2013cancer chemotherapy drugs in different matrices over the last four decades","volume":"130","author":"Pashaei","year":"2020","journal-title":"TrAC, Trends Anal Chem"},{"issue":"8","key":"10.1016\/j.xphs.2024.06.005_bib0018","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/15376516.2010.503246","article-title":"HPLC method development and validation for simultaneous detection of Arabinoside-C and doxorubicin","volume":"20","author":"Mistiran","year":"2010","journal-title":"Toxicol Mech Methods"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.06.005_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijpharm.2015.11.014","article-title":"HPLC analysis as a tool for assessing targeted liposome composition","volume":"497","author":"Oswald","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.06.005_bib0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.chroma.2016.12.080","article-title":"High performance liquid chromatography analysis of 100-nm liposomal nanoparticles using polymer-coated, silica monolithic columns with aqueous mobile phase","volume":"1484","author":"Itoh","year":"2017","journal-title":"J Chromatogr A"},{"issue":"3","key":"10.1016\/j.xphs.2024.06.005_bib0021","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/BF00262773","article-title":"HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids","volume":"21","author":"Camaggi","year":"1988","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10\u201312","key":"10.1016\/j.xphs.2024.06.005_bib0022","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0731-7085(91)80036-9","article-title":"HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients","volume":"9","author":"Beijnen","year":"1991","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2018.07.019","article-title":"Direct quantification of unencapsulated doxorubicin in liposomal doxorubicin formulations using capillary electrophoresis","volume":"549","author":"Ansar","year":"2018","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2024.06.005_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1021\/ac0260589","article-title":"HPLC of monolayer-protected gold nanoclusters","volume":"75","author":"Jimenez","year":"2003","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/mp3005337","article-title":"Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance","volume":"10","author":"Zhang","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.06.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.123043","article-title":"HPLC with fluorescence detection for the bioanalysis and pharmacokinetic study of Doxorubicin and Prodigiosin loaded on eco-friendly casein nanomicelles in rat plasma","volume":"1187","author":"Aboras","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"30","key":"10.1016\/j.xphs.2024.06.005_bib0027","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1016\/j.jchromb.2009.09.044","article-title":"Development and validation of a liquid chromatographic method for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites in plasma and saliva","volume":"877","author":"Maudens","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/separations5010009","article-title":"HPLC method development for quantification of doxorubicin in cell culture and placental perfusion media","volume":"5","author":"Shah","year":"2018","journal-title":"Separations"},{"key":"10.1016\/j.xphs.2024.06.005_bib0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.xphs.2023.11.035","article-title":"An automated electroanalytical method for the drug release profiling of liposomal doxorubicin HCl formulations","volume":"113","author":"Yurtsever","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2024.06.005_bib0030","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.xphs.2023.12.017","article-title":"An automated capillary electrophoresis based method for drug release profiling of liposomal doxorubicin","volume":"113","author":"Jayaraj","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2024.06.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462688","article-title":"Fast and versatile analysis of liposome encapsulation efficiency by nanoParticle exclusion chromatography","volume":"1662","author":"Bian","year":"2022","journal-title":"J Chromatogr A"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2017.11.035","article-title":"A simple and rapid measurement method of encapsulation efficiency of doxorubicin loaded liposomes by direct injection of the liposomal suspension to liquid chromatography","volume":"536","author":"Yamamoto","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2024.06.005_bib0033","first-page":"259","article-title":"Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet\u2013visible high performance liquid chromatography","volume":"2","author":"David","year":"2002","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"15","key":"10.1016\/j.xphs.2024.06.005_bib0034","doi-asserted-by":"crossref","first-page":"420A","DOI":"10.1021\/ac012495w","article-title":"Monolithic LC columns","volume":"73","author":"Tanaka","year":"2001","journal-title":"Anal Chem"},{"issue":"10","key":"10.1016\/j.xphs.2024.06.005_bib0035","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1248\/cpb.c17-00474","article-title":"Rapid analysis of DOXIL stability and drug release from DOXIL by HPLC using a glycidyl methacrylate-coated monolithic column","volume":"65","author":"Kimoto","year":"2017","journal-title":"Chem Pharm Bull"},{"issue":"4","key":"10.1016\/j.xphs.2024.06.005_bib0036","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bpj.2011.07.013","article-title":"Alcohol's effects on lipid bilayer properties","volume":"101","author":"Ing\u00f3lfsson","year":"2011","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2024.06.005_bib0038","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bpj.2016.11.3205","article-title":"Drunken membranes: short-chain alcohols alter fusion of liposomes to planar lipid bilayers","volume":"112","author":"Paxman","year":"2017","journal-title":"Biophys J"},{"key":"10.1016\/j.xphs.2024.06.005_bib0037","unstructured":"2022. Validation of analytical procedures Q2(R2). ed."},{"key":"10.1016\/j.xphs.2024.06.005_bib0039","doi-asserted-by":"crossref","unstructured":"Yaelle Schilt, Tal Berman, X. W, Einat Nativ-Roth, Yechezkel Barenholz, Raviv U. 2021. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs. BBA- general subjects 1865.","DOI":"10.1016\/j.bbagen.2021.129849"},{"issue":"1","key":"10.1016\/j.xphs.2024.06.005_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/cpb.c13-00587","article-title":"Thermotropic phase behavior of hydrogenated soybean phosphatidylcholine\u2013cholesterol binary liposome membrane","volume":"62","author":"Kitayama","year":"2014","journal-title":"Chem Pharm Bull"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T17:45:45Z","timestamp":1750095945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0022354924002272"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.06.005","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Robust Chromatographic Method for Drug Release profiling of liposomal doxorubicin HCl","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}